📑 What This Document Is

This document is a Proxy Statement (DEF 14A). Think of it as the official playbook for Xenon Pharmaceuticals' annual shareholder meeting. Since Xenon is a public company, the board must give shareholders a comprehensive guide detailing everything that will be voted upon, who is running the company, and what the rules are.

👉 Why it matters: Shareholders reading this need to understand that they aren't just seeing a financial report; they are being asked to vote on the company's leadership, its auditor, and its future compensation rules.

🏢 Xenon’s Corporate Identity

Xenon Pharmaceuticals Inc. is a biopharmaceutical company. While the filing doesn't detail its specific products, its governance structure confirms its deep involvement in the complex business of drug development and pharmaceutical science.

👉 The company's principal office is located at 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8, Canada.

📅 Annual Meeting Details

The annual meeting of Xenon’s shareholders is set to take place on Tuesday, June 2, 2026, starting at 9:30 a.m. (PDT).

👉 This meeting will be held virtually via live webcast at https://www.proxydocs.com/XENE. Only shareholders of record and duly appointed proxyholders can participate.

🏛️ Board of Directors 🧑‍⚖️

The Board of Directors (the Board) is the governing body that oversees the company's management. The nominees for election are the eight current directors: Dawn Svoronos, Gillian Cannon, Steven Gannon, Elizabeth Garofalo, Justin Gover, Patrick Machado, Ian Mortimer (President and CEO), and Gary Patou.

👉 Focus on Expertise: The Board emphasizes that its collective experience in the pharmaceutical industry is its strength. For example, Dr. Garofalo brings expertise in neurology and epilepsy, while Mr. Gannon has deep financial experience dating back to 1989.

Key Role of the CEO

Ian Mortimer, who has served as President and CEO since June 2021, was previously the Chief Financial Officer at Tekmira Pharmaceuticals. The Board believes his executive leadership and long tenure provide essential knowledge of the corporation.

🗳️ Voter Proposals: What Shareholders Decide

The proxy statement outlines eight distinct areas where shareholders will be asked to vote. These votes allow the owners of the company (the shareholders) to check the leadership and strategy of the executives.

💰 Financial Review (Item 1)

Shareholders will receive the audited annual financial statements for the year ended December 31, 2025, along with the auditor's report.

👔 Electing the Board (Item 2)

Shareholders vote on the election of the eight nominees for the Board. The Board needs the votes of the shareholders to elect the people who will govern the company in the coming years.

💵 Executive Compensation (Item 3 & 4)

Shareholders vote on two advisory matters concerning executive pay:

1. Say-on-Pay (Item 3): An advisory vote on the compensation of the named executive officers.
2. Frequency of Votes (Item 4): An advisory vote on how often future compensation votes should occur (options include "1 Year," "2 Years," "3 Years," or "ABSTAIN"). 👉 Why it matters: Because these are advisory votes, a failure to get majority support doesn't automatically void the pay structure, but it signals shareholder disapproval that the Board and executives must address.

🧪 Equity Incentive Plan (Item 5)

Shareholders vote to approve the 2026 Equity Incentive Plan. This plan allows the company to issue stock options and awards to employees and executives.

🧾 Auditors (Item 6 & 7)

The shareholders must vote to appoint PricewaterhouseCoopers LLP (PwC) as the Corporation’s auditor and authorize the Audit Committee to set the fee.

🤝 Governance Structure and Committees

The Board operates through a system of specialized standing committees to manage risk and oversight. This structure ensures that major decisions are reviewed by groups with specific expertise.

🔎 Audit Committee (The Financial Watchdog)

This committee oversees the company’s financial reporting and internal controls. Its current members are Mr. Gannon (Chair), Mr. Gover, and Mr. Machado.

• Key Function: They review the annual audit, monitor accounting practices, and oversee risk associated with investments and cybersecurity.
• Expert Confirmation: All three members are designated as Audit Committee financial experts and meet heightened independence standards.

⚖️ Nominating and Corporate Governance Committee (The People Planner)

This committee focuses on the Board’s structure and membership. Its current members are Ms. Svoronos (Chair), Dr. Cannon, and Dr. Garofalo.

• Key Function: They assess the performance of directors, recommend candidates for the Board, and oversee the company’s ESG (environmental, social, and governance) strategy.

💲 Compensation Committee (The Pay Plan)

This committee oversees how the company compensates its leaders. Its current members are Mr. Gover (Chair), Mr. Machado, and Dr. Patou.

• Key Function: They review and approve policies related to executive and employee compensation, including the issuance of stock options.

⚠️ Risk Management and Compliance

The Board takes a highly formal approach to risk management. Oversight is split among the committees:

• Audit Committee: Focuses on financial risks, including cybersecurity and data privacy.
• Compensation Committee: Focuses on risks associated with pay plans and arrangements.
• Nominating Committee: Focuses on risks related to director independence, conflicts of interest, and ESG matters.

Insider Trading Policies: The company has a strict policy governing buying or selling of company securities by directors, officers, and employees to ensure compliance with insider trading laws.

📅 Meeting Logistics & Voting Process

For the meeting to function, shareholders must follow specific rules.

📜 Voting Deadlines

All proxies for Common Shares must be received by the meeting administrator, Mediant/BetaNXT, no later than 11:59 p.m. (PDT) on Monday, June 1, 2026.

💻 Attending Virtually

The meeting is virtual-only. To participate or vote, shareholders must have a valid Control Number. Non-registered shareholders without a Control Number can attend as "guests" to listen but cannot vote or participate.

🧑‍🤝‍🧑 Beneficial Shareholders

This section reminds shareholders who hold stock through a broker (beneficial shareholders) that they must follow their broker's specific instructions. Their intermediary is crucial for ensuring their vote is counted.

📞 Important Contacts and Resources

For all proxy voting and procedural questions, shareholders must contact Mediant/BetaNXT.

• Email: [email protected]
• Phone: 1-866-648-8133
• Online Resource: Details on proxy materials and online voting are available via the company’s website.

---

💡 The Analogy

Running a massive pharmaceutical company is like directing a highly complex orchestra. The scientists are the musicians, the product is the music, and the Board of Directors and its committees (Audit, Compensation, etc.) are the conductors. This proxy statement isn't about the music itself, but about establishing the rules, appointing the conductors (the directors), and ensuring the payment structure (compensation) is fair and accountable for the next season.

🧩 Final Takeaway

The primary message is one of governance: Xenon is asking shareholders to formally approve its leadership, its financial oversight, and its compensation structure for 2026. These votes confirm who has the authority to steer the company's multi-billion dollar drug development efforts.